Lipopeptides from Bacillus subtilis AC7 inhibit adhesion and biofilm formation of Candida albicans on silicone
- 586 Downloads
Candida albicans is the major fungus that colonises medical implants, causing device-associated infections with high mortality. Antagonistic bacterial products with interesting biological properties, such as biosurfactants, have recently been considered for biofilm prevention. This study investigated the activity of lipopeptide biosurfactant produced by Bacillus subtilis AC7 (AC7 BS) against adhesion and biofilm formation of C. albicans on medical-grade silicone elastomeric disks (SEDs). Chemical analysis, stability, surface activities of AC7 BS crude extract and physicochemical characterisation of the coated silicone disk surfaces were also carried out. AC7 BS showed a good reduction of water surface tension, low critical micelle concentration, good emulsification activity, thermal resistance and pH stability. Co-incubation with 2 mg ml−1 AC7 BS significantly reduced adhesion and biofilm formation of three C. albicans strains on SEDs in a range of 67–69 % and of 56–57 %, respectively. On pre-coated SEDs, fungal adhesion and biofilm formation were reduced by 57–62 % and 46–47 %, respectively. Additionally, AC7 BS did not inhibit viability of C. albicans strains in both planktonic and sessile form. Chemical analysis of the crude extract revealed the presence of two families of lipopeptides, principally surfactin and a lower percentage of fengycin. The evaluation of surface wettability indicated that AC7 BS coating of SEDs surface was successful although uneven. AC7 BS significantly prohibits the initial deposition of C. albicans and slows biofilm growth, suggesting a potential role of biosurfactant coatings for preventing fungal infection associated with silicone medical devices.
KeywordsAnti-adhesion Biofilm Medical device Lipopeptide biosurfactant Coating Candida albicans
This work was partially funded by Regione Piemonte Grant POR-FESR Asse I—AGROBIOCAT Project.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Espinel-Ingroff A, Canton E, Martin-Mazuelos E, Pemán J (2009) Pharmacotherapy of Candida infections with echinocandins. Clin Med Insights Ther 1:889–897Google Scholar
- Fracchia L, Cavallo M, Allegrone G, Martinotti MG (2010) A Lactobacillus-derived biosurfactant inhibits biofilm formation of human pathogenic Candida albicans biofilm producers. In: Méndez-Vilas A (ed) Current research, technology and education topics in applied microbiology and microbial biotechnology. Formatex Research Center, Badajoz, pp 827–837Google Scholar
- Hegstad K, Langsrud S, Lunestad BT, Scheie AA, Sunde M, Yazdankhah SP (2010) Does the wide use of quaternary ammonium compounds enhance the selection and spread of antimicrobial resistance and thus threaten our health? Microb Drug Resist 16:91–104. doi: 10.1089/mdr.2009.0120 CrossRefPubMedGoogle Scholar
- Karchmer AV (2000) Infections of prosthetic valves and intravascular devices. In: Mandell G, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases. Churchill Livingstone, Elsevier, Philadelphia, pp 903–917Google Scholar
- Lazzell AL, Chaturvedi AK, Pierce CG, Prasad D, Uppuluri P, Lopez-Ribot JL (2009) Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother 64:567–570. doi: 10.1093/jac/dkp242 CrossRefPubMedGoogle Scholar
- Lee SC, Yoo JS, Kim SH et al (2006) Production and characterization of lipopeptide biosurfactant from Bacillus subtilis A8–8. J Microbiol Biotechnol 16:716–723Google Scholar
- Seydlová G, Svobodová J (2008) Review of surfactin chemical properties and the potential biomedical applications. Cent Eur J Med 3:123–133Google Scholar